C
Carinna Hockham
Researcher at The George Institute for Global Health
Publications - 34
Citations - 579
Carinna Hockham is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 6, co-authored 19 publications receiving 182 citations. Previous affiliations of Carinna Hockham include University of Oxford & University of New South Wales.
Papers
More filters
Journal ArticleDOI
Where are the women? Gender inequalities in COVID-19 research authorship.
Ana-Catarina Pinho-Gomes,Sanne A.E. Peters,Sanne A.E. Peters,Kelly Thompson,Carinna Hockham,Katherine Ripullone,Mark Woodward,Mark Woodward,Cheryl Carcel +8 more
TL;DR: Investigating whether gender differences existed in authorship of COVID-19 research since the onset of the pandemic found that women’s representation in research generally and specifically in the study of CO VID-19 may be disproportionately affected by lockdown measures.
Journal ArticleDOI
The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic review.
TL;DR: The COVID-19 pandemic has led to a substantial decrease in the rate of admissions for acute CVD, reductions in the number of procedures, shortened lengths of stay at the hospital and longer delays between the onset of the symptoms and hospital treatment.
Journal ArticleDOI
The spatial epidemiology of sickle-cell anaemia in India.
Carinna Hockham,Samir Bhatt,Roshan B. Colah,Malay B. Mukherjee,Bridget S. Penman,Bridget S. Penman,Sunetra Gupta,Frédéric B. Piel,Frédéric B. Piel +8 more
TL;DR: This work compiled a geodatabase of a substantial number of SCA surveys carried out in India over the last decade and generated the first India-specific model-based map of sickle-cell allele frequency which accounts for the district-level distribution of scheduled and non-scheduled populations.
Journal ArticleDOI
Prevalence of chronic kidney disease in Asia: a systematic review and analysis
Thaminda Liyanage,Tadashi Toyama,Carinna Hockham,Toshiharu Ninomiya,Vlado Perkovic,Mark Woodward,Masafumi Fukagawa,Kunihiro Matsushita,Kearkiat Praditpornsilpa,Lai Seong Hooi,Kunitoshi Iseki,Ming-Yen Lin,Heide A. Stirnadel-Farrant,Vivekanand Jha,Min Jun +14 more
TL;DR: The need for urgent collaborative action in Asia to prevent and manage CKD and its complications is shown, with the large number of people with CKD, and the substantial number with advanced CKD shown.
Journal ArticleDOI
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial
Nan Ye,Nan Ye,Meg Jardine,Meg Jardine,Megumi Oshima,Megumi Oshima,Carinna Hockham,Hiddo J.L. Heerspink,Rajiv Agarwal,George L. Bakris,Aletta E. Schutte,Aletta E. Schutte,Clare Arnott,Clare Arnott,Tara I. Chang,José Luis Górriz,Christopher P. Cannon,David M. Charytan,Dick de Zeeuw,Adeera Levin,Kenneth W. Mahaffey,Bruce Neal,Carol A. Pollock,David C. Wheeler,David C. Wheeler,Gian Luca Di Tanna,Hong Cheng,Vlado Perkovic,Vlado Perkovic,Brendon L. Neuen,Brendon L. Neuen +30 more
TL;DR: The CREDENCE trial as mentioned in this paper randomized people with Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) to canagliflozin or placebo.